Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Condensed Consolidated Statements of Operations
Net Revenues	$ 73,855	$ 48,625	$ 138,332	$ 103,146
Operating Expenses
Cost of sales (excluding depreciation and amortization)	35,294	22,314	69,565	42,299
Research and development	4,165	2,805	9,439	5,773
Selling, general, and administrative	31,958	18,820	60,775	36,407
Depreciation and amortization	13,764	11,324	28,321	22,222
Contingent consideration fair value adjustment	(1,095)		(342)	0
Legal settlement expense		8,400	0	8,400
Purified Cortrophin Gel pre-launch charges		515	0	553
Restructuring activities	2,570		2,570	0
Intangible asset impairment charge	112	0	112	0
Total Operating Expenses	86,768	64,178	170,440	115,654
Operating Loss	(12,913)	(15,553)	(32,108)	(12,508)
Other Expense, net
Interest expense, net	(6,669)	(2,531)	(13,282)	(4,985)
Other income/(expense), net	764	(67)	675	(582)
Loss Before Benefit for Income Taxes	(18,818)	(18,151)	(44,715)	(18,075)
Benefit for income taxes	3,895	4,045	9,662	4,055
Net Loss	(14,923)	(14,106)	(35,053)	(14,020)
Dividends on Series A convertible preferred stock	(407)		(812)	0
Net Loss Available to Common Shareholders	$ (15,330)	$ (14,106)	$ (35,865)	$ (14,020)
Basic and Diluted Loss Per Share:
Basic Loss Per Share	$ (0.94)	$ (1.17)	$ (2.21)	$ (1.16)
Diluted Loss Per Share	$ (0.94)	$ (1.17)	$ (2.21)	$ (1.16)
Basic Weighted-Average Shares Outstanding	16,272	12,085	16,205	12,045
Diluted Weighted-Average Shares Outstanding	16,272	12,085	16,205	12,045